Xi`an Eastling Biotech Co., Ltd.
Diamond Supplier
- Diamond
Supplier - 1st
years
Diamond Supplier
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Lab/Research institutions
Tel: +86-156-91766041
Mobile:
Tel: +86-156-91766041
Fax:
URL: http://www.eastlingbiotech.com/
Province/state: Shaanxi
City: Xi'an city
Street: No. 201, Unit 4, Building 9, Hongqi Community, Tanjia Street, Weiyang District, Xi 'an, Shaanxi
MaxCard:
Contact Suppliers
CAS NO.13647-35-3
98%(500-1000)Kilogram98%(100-500)Metric Ton
Trilostane
CAS: 13647-35-3
Molecular Formula: C20H27NO3
| Name | Trilostane |
| Synonyms | Vetoryl Trilostane TRILOSTANE 17-beta)-ph 17-hydroxy-3-oxo-4,5-epoxyandrostane-2-carbonitrile 4α,5-Epoxy-3,17β-dihydroxy-5α-androst-2-ene-2-carbonitrile 5a-Androstane-2a-carbonitrile, 4a,5-epoxy-17b-hydroxy-3-oxo- (4a,5a,17b)-3,17-Dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4a,5a,17b)- (4alpha,5alpha,17beta)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile (2-alpha,4-alpha,5-alpha,17-beta)-4,5-epoxy-17-hydroxy-3-oxoandrostane-2-car |
| CAS | 13647-35-3 |
| EINECS | 237-133-0 |
| InChI | InChI=1/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1 |
| InChIKey | KVJXBPDAXMEYOA-CXANFOAXSA-N |
| Molecular Formula | C20H27NO3 |
| Molar Mass | 329.43 |
| Density | 1.1213 (rough estimate) |
| Melting Point | 264 °C |
| Boling Point | 467.02°C (rough estimate) |
| Specific Rotation(α) | D25 +137.4° (c = 1 in pyridine) |
| Flash Point | 254.8°C |
| Solubility | DMSO: ≥17mg/mL |
| Vapor Presure | 5.39E-12mmHg at 25°C |
| Appearance | powder |
| Color | white to tan |
| pKa | 8.57±0.70(Predicted) |
| Storage Condition | 2-8°C |
| Refractive Index | 1.5614 (estimate) |
| In vitro study | Both Trilostane and 4-Hydroxytamoxifen (OHT) affect the transcription of genes involved in cell cycle regulation, cell adhesion, and matrix formation, however, only 12.5 percent of Trilostane down-regulated genes and 9.2 percent of up-regulated genes were similar in MCF-7 cells. |
| In vivo study | Trilostane treatment leads to a significant decrease in basal plasma cortisol concentration in dogs Trilostane treatment leads to a significant decrease in plasma aldosterone concentration (PAC) but median plasma renin activity (PRA(265 fmol/L/s) significantly higher than before treatment (115 fmol/L/s). Trilostane affects both the hypothalamic-pituitary-adrenal cortex and the renin-aldosterone axis. In Dahlsalt-sensitive rats, Trilostane was effective in increasing systolic blood pressure and reversing the high pressure generated in by drinking 0.9% saline. Trilostane was equally effective in female and male rats. In all cats, Trilostane reduced clinical symptoms and improved endocrine test results, but insulin requirements did not change, and all continued some signs of hypercortisolemia. In PDH dogs, Trilostane caused a decrease in serum cortisol and aldosterone concentrations, although the decrease in serum aldosterone concentrations was less than that of serum cortisol concentrations. |
| EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
| indication | triptan can inhibit 3 β-dehydrogenase in the process of corticosteroid synthesis, and reduce the synthesis of cortisol and aldosterone, it is clinically used to treat Cushing's syndrome (hypercortisolism) and primary aldosteronism, but it is not as effective as metilapone in treating Cushing's syndrome (hypercortisolism). This product also has a significant role in reducing blood testosterone levels, may be related to the inhibition of its synthesis. |
| treatment history | , 5 α-epoxy-2-cyano-androst-2-ene-3, 17 β-diol reversibly inhibits 3 β-hydroxysteroid dehydrogenase and Δ5, 4-isomerase, which blocks the biosynthesis of mineralocorticoids and glucocorticoids, was approved in the UK in 1980 for the treatment of hyperaldosteronism and hypercortisolism, it was approved for the treatment of Cushing's syndrome or hyperadrenocortical syndrome in the United States in 1985. Given that older animals, especially older dogs, are predisposed to Cushing's syndrome, and that trolostine can alleviate symptoms and improve quality of life in more than 90% of dogs, so the drug is also approved for veterinary use in the UK. Triptan itself has no hormonal activity, so its side effects are less, and its safety and tolerability are particularly good. |
| mechanism of action | Breast cancer is a hormone-dependent tumor, and estrogen is the main driver of cancer cell growth. Therefore, one of the modern major therapies for breast cancer is to target estrogen by inhibiting estrogen production or blocking the action of estrogen at its site of action, the estrogen receptor. The estrogen receptor has been considered to be a single receptor, but recent studies have identified at least two subtypes, alpha and beta. Estrogen binding to α-estrogen receptor can stimulate cell growth, but binding to β-estrogen receptor can down-regulate α-estrogen receptor and slow down cell proliferation rate. Studies have revealed that in addition to reducing the production of estrogen, triptan can also regulate the binding of estrogen to different subtypes of estrogen receptors, at the same time, the dual effects of α-estrogen receptor inhibitor and β-estrogen receptor agonist are manifested, and the negative effect of estrogen on cancer cells is finally blocked and changed. The unique mode of action of triptan not only distinguishes it from other anti-estrogens currently available, but is also the pharmacological basis for its still highly effective treatment of failed or resistant breast cancer with other anti-estrogen therapies. |
| treatment of advanced breast cancer | Breast cancer is the most common tumor type in women. At present, for postmenopausal patients with hormone receptor-positive or unknown type of breast cancer, clinical consistently recommend the preferred anti-estrogen therapy, and this therapy in patients with disease progression, the role of improving survival time has long been affirmed and confirmed by a large number of studies. A new drug, modlenal, developed by Bioenvision, a biotechnology company, is available to treat postmenopausal women whose hormone-selective cancer has spread outside the mammary gland, the drug is administered in two ways to slow disease progression. For hormone-sensitive breast cancer, estrogen promotes the growth of cancer cells by acting on two receptors. Estrogen а is like a cancer accelerator, and estrogen receptor β is a brake. Modrenal enhances the adsorption of estrogen to estrogen receptor beta and attenuates the effect on estrogen receptor а. It also acts on another site on the cell's DNA, AP1, to reduce cell proliferation. |
| biological activity | Trilostane (WIN 24540) is a 3β hydroxysteroid dehydrogenase inhibitor used in the treatment of Cushing's syndrome. |
Mol Download Chemical properties
CAS:
13647-35-3
MF:
C20H27NO3
MW:
329.43
EINECS:
237-133-0
MDL No.:
MFCD00199295
Melting point:
264 °C
alpha
D25 +137.4° (c = 1 in pyridine)
Boiling point:
467.02°C (rough estimate)
Density
1.1213 (rough estimate)
refractive index
1.5614 (estimate)
storage temp.
2-8°C
solubility
DMSO: ≥17mg/mL
pka
8.57±0.70(Predicted)
form
powder
color
white to tan
InChIKey
KVJXBPDAXMEYOA-CXANFOAXSA-N
SMILES
[C@@]123CC[C@@]4([H])[C@]5([H])CC[C@H](O)[C@@]5(C)CC[C@]4([H])[C@@]1(C)CC(C#N)=C(O)[C@@]2([H])O3 |&1:0,3,5,9,11,15,17,25,r|
Xi'an Eastling biotech Co., Ltd. is dedicated to the research and development, production, and sales of natural plant extracts; With nearly 15 years of experience in identifying, researching, developing, and producing active ingredients for medicinal plants, we focus on providing innovative products and services to customers in industries such as pharmaceuticals, health food, and cosmetics.
Eastling Biotechnology has established a global direct harvesting system for plant raw materials, ensuring the high quality and authenticity of raw materials, while also protecting the continuity and diversity of plants; Having strong research and development capabilities, we can develop more effective and specialized plant active ingredients for the pharmaceutical, health food, and cosmetics industries; We have established an advanced quality control system, and the quality control of our products depends on advanced testing instruments and high-level technical experts. The effective combination of the two forms Eastling's ability to quickly and rigorously control product quality.
We have a production system that complies with Chinese GMP and American cGMP certifications, as well as advanced and optimized large-scale industrial production technology. In addition to producing specific products for Eastling Biotechnology, we also provide customized services to meet the characteristics and needs of different customers to produce customized products.
We believe that natural active ingredients are the foundation of our service to customers. Scientific and effective production technology is the foundation for us to provide customers with specialized products. We have the ability to serve customers in the pharmaceutical, health food, and cosmetics industries, provide new product solutions, and add new value to their products.